STI571是近年来研制的一种特异的bcr蛳abl激酶抑制剂,由于它能抑制慢性粒细胞白血病(CML)酪氨酸激酶的活性,针对CML的分子异常进行一种靶向治疗,已被欧美等国广泛应用于临床上治疗慢性粒细胞白血病,目前STI571在C蛳Kit阳性肿瘤:肥大细胞增多症、胃肠间质肿瘤、小细胞肺癌、急性髓性白血病中的作用也越来越受到人们的关注。就近年来该方面的研究进展进行综述。 STI571 is a specific bcr 蛳 abl kinase inhibitor developed in recent years. STI571 is a targeted therapy for molecular abnormalities of CML because it inhibits the activity of CML tyrosine kinase. And other countries are widely used clinically in the treatment of chronic myeloid leukemia, the current STI571 in C 蛳 Kit positive tumors: mastocytosis, gastrointestinal stromal tumors, small cell lung cancer, acute myelogenous leukemia in the role of more and more people s concern. In recent years, the research progress in this area are reviewed.